Form 4: Cartesian Therapeutics Director Kalayoglu Acquires Shares and Stock Options

Director Murat Kalayoglu reports acquisition of common stock and stock options in Cartesian Therapeutics.

Summary

• On January 2, 2025, Murat Kalayoglu, a director and 10% owner of Cartesian Therapeutics, acquired 2,600 shares of common stock.
• These shares were acquired at a price of $0.
• Kalayoglu also acquired 7,800 stock options with an exercise price of $16.93, exercisable from January 2, 2026, and expiring on January 1, 2035.
• Following these transactions, Kalayoglu directly owns 508,977 shares of common stock and indirectly owns 4,555,260 shares through a trust.
• The 2,600 shares of common stock were acquired in the form of Restricted Stock Units (RSUs) which will vest in full on January 2, 2026.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard insider transaction report. The acquisition of shares and options by a director is generally viewed as a positive sign, but without additional context, it's difficult to gauge the overall impact.

Positives

• The acquisition of shares and stock options by a director could be interpreted as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are standard disclosures required by the SEC to ensure transparency in insider trading activities, providing investors with insights into the actions of company insiders.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, as insider buying is often seen as a sign of confidence in the company's prospects.

Key Dates